Skip to main content

Therapeutic Proteins to Cells

Engineered Extracellular Vesicles Could Deliver Gene Editors, Therapeutic Proteins to Cells




New research from scientists at the Karolinska Institutet in Sweden and their collaborators elsewhere describes a way of improving extracellular vesicles’ ability to transport things like therapeutic proteins and gene editors into cells. Specifically, their approach involves adding a small part of a bacterial protein called an intein and a fusogenic protein from a virus to the vesicles.

Full details are provided in a new Nature Communications paper titled, “Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors.” In the paper, the researchers explain that their work offers solutions to the “major bottlenecks of EV-mediated delivery of protein therapeutics, the enrichment of liberated active cargo into EVs, and their subsequent endosomal escape in recipient cells.” The added fusogenic protein, vesicular stomatitis virus G glycoprotein, helps the engineered vesicles fuse with the endosomal membrane and release their contents in the cell. Meanwhile, the added intein, which is derived from Mycobacterium tuberculosis recA, can cut itself to help release the therapeutic proteins inside the cell.

In experiments using cells and live animals, the researchers report being able to efficiently deliver Cre recombinase, a protein that can cut and paste DNA, and Cas9/sgRNA complexes for editing genes. When the extracellular vesicles loaded with Cre recombinase were injected into mice brains, the scientists observed a significant change in cells of the hippocampus and cortex. Specifically, the mice had “greater than 40% and 30% recombined cells in the hippocampus and cortex, respectively,” the researchers wrote. They also demonstrated how the technique could be used to treat systemic inflammation in mice by using engineered vesicles to deliver a super-repressor of NF-ĸB activity.

Commenting on the study, Samir EL Andaloussi, PhD, senior author on the study and a professor in Karolinska’s department of laboratory medicine, said that the engineering strategy overcomes barriers such as “poor endosomal escape and limited intracellular release.” Furthermore, “our in vivo findings highlight the potential of engineered EVs as a versatile platform for delivering therapeutics to treat a broad range of conditions, including systemic inflammation, genetic diseases, and neurological disorders,” he said.

Xiuming Liang, PhD, first author on the study and a research specialist in the department of laboratory medicine at Karolinska, added that “improving the efficiency and reliability of therapeutic delivery into target cells” could “significantly broaden the application of advanced medicines.” It opens up the possibility of using “CRISPR/Cas9 gene scissors or similar tools to treat severe genetic diseases of the central nervous system, such as Huntington’s disease and spinal muscular atrophy,” he said.

gene expression, genetic mutation, DNA sequencing, genome editing, CRISPR-Cas9, hereditary traits, gene therapy, molecular genetics, transcription factors, RNA splicing, epigenetics, SNP analysis, genome mapping, recombinant DNA, genetic code, protein synthesis, genotype, phenotype, chromosomal abnormalities, gene regulation

#GeneExpression, #GeneticMutation, #DNASequencing, #GenomeEditing, #CRISPRCas9, #HereditaryTraits, #GeneTherapy, #MolecularGenetics, #TranscriptionFactors, #RNASplicing, #Epigenetics, #SNPAnalysis, #GenomeMapping, #RecombinantDNA, #GeneticCode, #ProteinSynthesis, #Genotype, #Phenotype, #ChromosomalAbnormalities, #GeneRegulation

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...